Details of the Drug Combination

General Information of Drug Combination (ID: DC3T71J)

• Drug Combination Name: DFN-15 + Taxol
• Indication: Renal cell carcinoma; Status: Investigative [1]
• Component Drugs:
  DFN-15 (DM3BF9B): N.A.
  Taxol (DMUOT9V): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: UO-31
  Zero Interaction Potency (ZIP) Score: 0.14
  Bliss Independence Score: 5.52
  Loewe Additivity Score: 2.82
  LHighest Single Agent (HSA) Score: 3.9

Molecular Interaction Atlas of This Drug Combination

Indication(s) of DFN-15

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 3	[2]

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[3]
Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Pancreatic cancer	2C10	Phase 3	[5]
Gastric adenocarcinoma	2B72	Phase 2	[6]
Ovarian cancer	2C73	Phase 2	[6]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[3]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Astrocytoma	DCPI08Q	U251	Investigative	[1]
Clear cell renal cell carcinoma	DCSNZAC	786-0	Investigative	[1]
Clear cell renal cell carcinoma	DCGNPDY	A498	Investigative	[1]
Glioblastoma	DCSXDDC	SNB-75	Investigative	[1]
Glioma	DCB0A4D	SF-268	Investigative	[1]
Glioma	DC9MBVJ	SF-295	Investigative	[1]
Breast adenocarcinoma	DCRKTDX	MDA-MB-468	Investigative	[7]
Colon carcinoma	DCOOPCN	KM12	Investigative	[7]
Invasive ductal carcinoma	DCI1ARZ	BT-549	Investigative	[7]
Adenocarcinoma	DC0J66X	HT29	Investigative	[8]
Large cell lung carcinoma	DCL1G2S	NCI-H460	Investigative	[8]
Lung adenocarcinoma	DCFSRKM	MDA-MB-231	Investigative	[8]
Mixed endometrioid and clear cell carcinoma	DCJCY6M	IGROV1	Investigative	[8]
Ovarian serous cystadenocarcinoma	DC7IV5F	SK-OV-3	Investigative	[8]
Prostate carcinoma	DCOMFQQ	PC-3	Investigative	[8]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [8] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.